Study question Is there an influence of mRNA COVID-19 vaccine on ovarian response and in vitro fertilization (IVF) treatment outcomes? Summary answer COVID-19 mRNA vaccine did not affect the ovarian response nor pregnancy rates in IVF treatment What is known already Studies demonstrated that infection with COVID-19 during pregnancy increased the risk of the development of severe disease and pregnancy complications. A recent meta-analysis of international data showed a declining tendency to be vaccinated, possibly influenced by public concerns over safety of the vaccines. Specifically, concerns were raised about a possible detrimental effect on fertility and pregnancy outcomes due to similarity between syncytin-1, a human placental fusion protein, and the SARS-CoV-2 spike protein expressed after administration of the COVID-19 vaccine. To date, only one retrospective analysis on 36 infertility patients has assessed the influence of COVID-19 vaccination on IVF treatment outcomes. Study design, size, duration A retrospective cohort study . The study included a total of 400 patients, 200 vaccinated women and 200 age matched non-vaccinated women, undergoing IVF treatments during January-April 2021. Participants/materials, setting, methods All vaccinated women aged 20-42 that underwent IVF treatment cycles between January 1, 2021 and April 31 2021 were included. All participants completed two doses of the BNT162b2 (Pfizer-BioNTech) vaccine at least two weeks before starting ovarian stimulation. The study group was matched by age to non-vaccinated patients that underwent IVF treatments during the same period. Patients with a positive COVID 19 test in the past were excluded. Main results and the role of chance Two hundred patients underwent oocyte retrieval 14-68 days after receiving COVID-19 vaccination. No difference was found between vaccinated and non-vaccinated patients in mean number of oocytes retrieved per cycle (10.63 vs 10.72, p = 0.93). Among 128 vaccinated patients and 133 non-vaccinated patients that underwent fresh embryos transfers, no difference was demonstrated in clinical pregnancy rates (32.8% vs. 33.1%, p-value=0.96), 42 and 44 pregnancies respectively. The fertilization rates and mean number of cryopreserved embryos were similar between the two groups in freeze all cycles (55.43% vs. 54.29%, p-value=0.73), (3.59 vs. 3.28, p-value=0.80). Among vaccinated patients and non-vaccinated patients that underwent fresh embryos transfers, no difference was demonstrated in the fertilization rate (64.81% vs. 61.98%, p = 0.51), and transferred embryos quality. Regression models applied demonstrated no effect of the vaccine on oocyte yields and pregnancy rates. Limitations, reasons for caution Limitations include retrospective nature and different treatment protocols. Additional limitation is the lack of information about vaccination status of the partners. One would assume that if unbalanced, the proportion of vaccinated males would be higher in the study group as partners tend to choose similarly in regard to vaccine administration. Wider implications of the findings Women should consider vaccination prior to their attempts to conceive via IVF treatments. Trial registration number ASF-0094-21

中文翻译：

---

P-710 COVID-19 疫苗接种和不孕症治疗结果

研究问题 mRNA COVID-19 疫苗对卵巢反应和体外受精 (IVF) 治疗结果有影响吗？摘要答案 COVID-19 mRNA 疫苗不影响体外受精治疗中的卵巢反应或妊娠率 已知研究表明，妊娠期间感染 COVID-19 会增加发生严重疾病和妊娠并发症的风险。最近对国际数据的一项荟萃​​分析显示，接种疫苗的趋势正在下降，这可能是受到公众对疫苗安全性担忧的影响。具体而言，由于人类胎盘融合蛋白 syncytin-1 与接种 COVID-19 疫苗后表达的 SARS-CoV-2 刺突蛋白之间的相似性，人们担心这可能对生育和妊娠结局产生不利影响。迄今为止，只有一项对 36 名不孕症患者的回顾性分析评估了 COVID-19 疫苗接种对 IVF 治疗结果的影响。研究设计、规模、持续时间 一项回顾性队列研究。该研究包括在 2021 年 1 月至 2021 年 4 月期间接受 IVF 治疗的总共 400 名患者、200 名接种疫苗的女性和 200 名年龄匹配的未接种疫苗的女性。参与者/材料、设置、方法所有接受 IVF 治疗周期的 20-42 岁接种疫苗的女性包括 2021 年 1 月 1 日和 2021 年 4 月 31 日。所有参与者在开始卵巢刺激前至少两周完成了两剂 BNT162b2 (Pfizer-BioNTech) 疫苗。研究组按年龄与同期接受体外受精治疗的未接种疫苗的患者相匹配。过去 COVID 19 检测呈阳性的患者被排除在外。主要结果和机会的作用 200 名患者在接受 COVID-19 疫苗接种后 14-68 天接受了取卵。接种疫苗和未接种疫苗的患者每个周期取卵的平均数量没有差异（10.63 vs 10.72，p = 0.93）。在接受新鲜胚胎移植的 128 名接种疫苗的患者和 133 名未接种疫苗的患者中，临床妊娠率（32.8% 对 33.1%，p 值=0.96）、42 次和 44 次妊娠率无差异。在冷冻所有周期中，两组的受精率和平均冷冻保存胚胎数相似（55.43% 对 54.29%，p 值=0.73），（3.59 对 3.28，p 值=0.80）。在接受新鲜胚胎移植的接种疫苗患者和未接种疫苗患者中，受精率无差异（64.81% vs. 61.98%，p = 0.51）和移植胚胎质量。应用的回归模型表明疫苗对卵母细胞产量和妊娠率没有影响。限制，谨慎的原因 限制包括回顾性和不同的治疗方案。额外的限制是缺乏有关合作伙伴疫苗接种状态的信息。有人会假设，如果不平衡，研究组中接种疫苗的男性比例会更高，因为合作伙伴倾向于在疫苗接种方面做出类似选择。研究结果的更广泛影响 女性在尝试通过 IVF 治疗怀孕之前应考虑接种疫苗。试用注册号 ASF-0094-21 限制，谨慎的原因 限制包括回顾性和不同的治疗方案。额外的限制是缺乏有关合作伙伴疫苗接种状态的信息。有人会假设，如果不平衡，研究组中接种疫苗的男性比例会更高，因为合作伙伴倾向于在疫苗接种方面做出类似选择。研究结果的更广泛影响 女性在尝试通过 IVF 治疗怀孕之前应考虑接种疫苗。试用注册号 ASF-0094-21 限制，谨慎的原因 限制包括回顾性和不同的治疗方案。额外的限制是缺乏有关合作伙伴疫苗接种状态的信息。有人会假设，如果不平衡，研究组中接种疫苗的男性比例会更高，因为合作伙伴倾向于在疫苗接种方面做出类似选择。研究结果的更广泛影响 女性在尝试通过 IVF 治疗怀孕之前应考虑接种疫苗。试用注册号 ASF-0094-21 研究组中接种疫苗的男性比例会更高，因为合作伙伴倾向于在疫苗接种方面做出类似选择。研究结果的更广泛影响 女性在尝试通过 IVF 治疗怀孕之前应考虑接种疫苗。试用注册号 ASF-0094-21 研究组中接种疫苗的男性比例会更高，因为合作伙伴倾向于在疫苗接种方面做出类似选择。研究结果的更广泛影响 女性在尝试通过 IVF 治疗怀孕之前应考虑接种疫苗。试用注册号 ASF-0094-21